Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 18:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
NCT06267872 · National Institute of Allergy and Infectious Diseases (NIAID) · PHASE1 · withdrawn · last registry update 2025-03-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “FDA Clinical Hold” | – | Registry record, National Institute of Allergy and Infectious Diseases (NIAID) |
Also happening at the time. Not shown to be a cause.
No drug target was found for this trial's interventions, so there is no same-target timeline.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision